TransMedics Total Stockholder Equity from 2010 to 2025

TMDX Stock  USD 57.20  0.82  1.41%   
TransMedics Total Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Total Stockholder Equity is likely to outpace its year average in 2025. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
2018-03-31
Previous Quarter
189.9 M
Current Value
209.9 M
Quarterly Volatility
107.7 M
 
Covid
Check TransMedics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TransMedics' main balance sheet or income statement drivers, such as Interest Expense of 13 M, Selling General Administrative of 144.4 M or Research Development of 76.4 M, as well as many indicators such as Price To Sales Ratio of 11.6, Dividend Yield of 0.0 or PTB Ratio of 17.68. TransMedics financial statements analysis is a perfect complement when working with TransMedics Valuation or Volatility modules.
  
Check out the analysis of TransMedics Correlation against competitors.

Latest TransMedics' Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of TransMedics Group over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. TransMedics' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TransMedics' overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Slightly volatile
   Total Stockholder Equity   
       Timeline  

TransMedics Total Stockholder Equity Regression Statistics

Arithmetic Mean(15,888,143)
Coefficient Of Variation(867.99)
Mean Deviation124,588,107
Median(4,825,000)
Standard Deviation137,906,774
Sample Variance19018.3T
Range356.1M
R-Value0.87
Mean Square Error4921.5T
R-Squared0.76
Significance0.000011
Slope25,226,828
Total Sum of Squares285274.2T

TransMedics Total Stockholder Equity History

2025165.7 M
2024157.8 M
2023137.2 M
2022187.4 M
202167.9 M
2020103.9 M
201954.6 M

About TransMedics Financial Statements

TransMedics investors use historical fundamental indicators, such as TransMedics' Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TransMedics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Stockholder Equity157.8 M165.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TransMedics Stock Analysis

When running TransMedics' price analysis, check to measure TransMedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TransMedics is operating at the current time. Most of TransMedics' value examination focuses on studying past and present price action to predict the probability of TransMedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TransMedics' price. Additionally, you may evaluate how the addition of TransMedics to your portfolios can decrease your overall portfolio volatility.